Document is current
Any future updates will be listed below
-
Authors
Thisted, Thomas
Biesova, Zuzana
Walmacq, Celine
Stone, Everett
Rodnick-Smith, Max
Ahmed, Shaheda S.
Horrigan, Stephen K.
Van Engelen, Bo
Reed, Charles
Kalnik, Matthew W.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R43DA044064)
- License Information
-
More Information
Article History
Received: 9 May 2019
Accepted: 23 July 2019
First Online: 2 August 2019
Ethics approval and consent to participate
: Rat and mouse studies conducted at Noble Life Sciences (NLS) followed the NIH guide for Care and Use of Laboratory Animals (8th ed.) and all protocols were approved by NLS Institutional Animal Care and Use Committee. NLS is an AAALACi accredited and USDA Licensed (51-12-0092) and OLAW Assured (A4633–01) facility.Peripheral blood (60 mL) was obtained from healthy volunteers (<i>n</i> = 5) after receiving their written informed consent. Local Research Ethics Committee (LREC, Northeast Newcastle, UK) approval was granted prior to study commencement.
: Not applicable.
: TT, ZB, CW and MK are or have been employees and shareholders of Antidote Therapeutics, Inc. (Antidote Tx). CR is a consultant to Antidote Tx and shareholder. MK and TT are co-inventors on the following patent application: “Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning” PCT/US2016/045109 WO/2017/023904. MK, TT, ES, CR, and MRS are co-inventors on the following patent application: “Novel Nicotine-Degrading Enzyme Variants.” PCT/US2018/016664 WO/2018/144879. ES and MRS, have received research funding from Antidote Tx. Alcyomics, SA’s employer, was reimbursed by Antidote Tx for the cost of conducting the in vitro human assays.
